{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:14:14Z","timestamp":1783779254843,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jiangsu Medical Association","award":["SYH-32099-0123 (2024027)"],"award-info":[{"award-number":["SYH-32099-0123 (2024027)"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk stratification provided by noninvasive tests (NITs) for fibrosis in large populations require further characterization. Specifically, the degree of agreement between different NITs and how their association with metabolic comorbidities varies in Chinese MASLD cohorts remains unclear. This study aimed to systematically evaluate the prevalence of MASLD and to compare the performances among 3 NITs for fibrosis in a large eastern Chinese cohort. In this cross-sectional study, which included 201,616 adults from eastern China between January 01, 2021 and March 31, 2025, MASLD was diagnosed based on hepatic steatosis on ultrasonography plus metabolic criteria according to the latest guidelines. Liver fibrosis was assessed using the FIB-4 index, nonalcoholic fatty liver disease fibrosis score (NFS), and aspartate transaminase to platelet ratio index (APRI). Sex-and age-standardized prevalence was calculated. Associated factors were analyzed via multivariable logistic regression. The standardized prevalence of MASLD was 39.42%, higher in males (49.98%) than females (28.59%), with obesity as the strongest risk factor (aOR: 7.69). Among MASLD patients, significant fibrosis prevalence was similar when assessed by FIB-4 (19.12%) and NFS (21.32%); advanced fibrosis was lowest according to APRI (0.61%) compared to FIB-4 (1.79%) and NFS (1.97%). Critically, the associations between metabolic comorbidities (e.g., diabetes, dyslipidemia) and fibrosis risk varied substantially depending on the NIT used. MASLD is highly prevalent in this eastern Chinese health checkup cohort. The marked discordance in fibrosis risk stratification across different NITs, particularly in patients with metabolic comorbidities, highlights that these tools provide complementary rather than interchangeable information. These findings suggest the need for cautious interpretation of NIT results and further research into context-aware risk stratification strategies that consider both the specific NIT employed and the patient\u2019s metabolic profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049110","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:00:26Z","timestamp":1780718426000},"page":"e49110","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology of metabolic dysfunction-associated steatotic liver disease and discordance in non-invasive fibrosis scores in Eastern China: A cross-sectional study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-1299","authenticated-orcid":false,"given":"Mingxing","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Health Management Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Health Management Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Health Management Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260711","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"R2-20260711","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s42255-024-01190-w","article-title":"Diabetes in China: epidemiology, pathophysiology and multi-omics.","volume":"7","author":"Jia","year":"2025","journal-title":"Nat Metab"},{"key":"R3-20260711","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/CM9.0000000000002189","article-title":"Obesity pandemic in China: epidemiology, burden, challenges, and opportunities.","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R4-20260711","doi-asserted-by":"crossref","first-page":"e0423","DOI":"10.1097\/HC9.0000000000000423","article-title":"Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis.","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"key":"R5-20260711","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease.","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R6-20260711","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R7-20260711","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/liv.15555","article-title":"The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.","volume":"43","author":"Kugelmas","year":"2023","journal-title":"Liver Int"},{"key":"R8-20260711","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR Trials.","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"R9-20260711","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/a-2082-5203","article-title":"Screening for at-risk nonalcoholic fatty liver disease in the primary care setting.","volume":"43","author":"Urias","year":"2023","journal-title":"Semin Liver Dis"},{"key":"R11-20260711","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"R12-20260711","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","article-title":"Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project).","volume":"390","author":"Lu","year":"2017","journal-title":"Lancet"},{"key":"R13-20260711","doi-asserted-by":"crossref","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 Chinese guideline for lipid management.","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"R14-20260711","first-page":"261","article-title":"Current modalities of fibrosis assessment in non-alcoholic fatty liver disease.","volume":"5","author":"Cheah","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"R15-20260711","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/liv.14828","article-title":"Prevalence of NAFLD, MASLD and associated advanced fibrosis in the contemporary United States population.","volume":"41","author":"Ciardullo","year":"2021","journal-title":"Liver Int"},{"key":"R16-20260711","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/ejhf.70053","article-title":"Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.","volume":"27","author":"Huber","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"R17-20260711","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.15010","article-title":"Burden of liver complications related to non-alcoholic fatty liver disease in China from 2005 to 2019: observations from the Global Burden of Disease Study, 2019.","volume":"25","author":"Liu","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R18-20260711","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"R19-20260711","doi-asserted-by":"crossref","first-page":"e70132","DOI":"10.1002\/edm2.70132","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances.","volume":"8","author":"Miller","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"R20-20260711","doi-asserted-by":"crossref","first-page":"921504","DOI":"10.3389\/fendo.2022.921504","article-title":"Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes.","volume":"13","author":"Lizcano","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R21-20260711","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41419-025-07331-7","article-title":"Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease.","volume":"16","author":"Smiriglia","year":"2025","journal-title":"Cell Death Dis"},{"key":"R22-20260711","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1210\/endrev\/bnaf018","article-title":"The Impact of estrogen deficiency on liver metabolism: implications for hormone replacement therapy.","volume":"46","author":"Dong","year":"2025","journal-title":"Endocr Rev"},{"key":"R23-20260711","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.3390\/ijms26199625","article-title":"Diet and lifestyle interventions in metabolic dysfunction-associated fatty liver disease: a comprehensive review.","volume":"26","author":"Sheikh","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R24-20260711","doi-asserted-by":"crossref","first-page":"1256081","DOI":"10.3389\/fendo.2023.1256081","article-title":"Platelet-rich plasma for the treatment of diabetic foot ulcer: a systematic review.","volume":"14","author":"OuYang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R25-20260711","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.3350\/cmh.2024.0351","article-title":"Prevalence of clinically significant liver fibrosis in the general population: a systematic review and meta-analysis.","volume":"30","author":"Kim","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"R26-20260711","doi-asserted-by":"crossref","first-page":"101407","DOI":"10.1016\/j.jceh.2024.101407","article-title":"A validation study of non-invasive scoring systems for assessing severity of hepatic fibrosis in a cohort of South Indian patients with non-alcoholic fatty liver disease.","volume":"14","author":"Mathew","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"R27-20260711","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"R28-20260711","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R29-20260711","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/cells12172129","article-title":"Liver injury and regeneration: current understanding, new approaches, and future perspectives.","volume":"12","author":"Hora","year":"2023","journal-title":"Cells"},{"key":"R30-20260711","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41467-020-16092-0","article-title":"Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis.","volume":"11","author":"An","year":"2020","journal-title":"Nat Commun"},{"key":"R31-20260711","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s12072-022-10395-8","article-title":"Association between metabolically healthy obesity and non-alcoholic fatty liver disease.","volume":"16","author":"Man","year":"2022","journal-title":"Hepatol Int"},{"key":"R32-20260711","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1007\/s10620-021-07099-8","article-title":"Visceral adipose tissue inflammation and radiographic visceral-to-subcutaneous adipose tissue ratio in patients with cirrhosis.","volume":"67","author":"Ha","year":"2022","journal-title":"Dig Dis Sci"},{"key":"R33-20260711","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.3390\/ijms25115807","article-title":"The renin-angiotensin system in liver disease.","volume":"25","author":"McGrath","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R34-20260711","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis.","volume":"112","author":"Kamal","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R35-20260711","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/apt.17809","article-title":"Editorial: Paradox of liver fat content in the spectrum of non-alcoholic fatty liver disease.","volume":"59","author":"Chung","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-20260711","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:00:31Z","timestamp":1783778431000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":35,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049110","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"2026-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}